Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system
We have utilized a human tumor cloning system to determine the in vitro antitumor effects of elliptinium, a new DNA intercalating agent. The purpose was to determine which human tumors should be studied in phase II clinical trials with this agent. Eighty-eight out of 282 tumors plated in culture wer...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer & clinical oncology 1987-11, Vol.23 (11), p.1621-1626 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1626 |
|---|---|
| container_issue | 11 |
| container_start_page | 1621 |
| container_title | European journal of cancer & clinical oncology |
| container_volume | 23 |
| creator | Arteaga, Carlos L. Kisner, Daniel L. Goodman, Anita Von Hoff, Daniel D. |
| description | We have utilized a human tumor cloning system to determine the
in vitro antitumor effects of elliptinium, a new DNA intercalating agent. The purpose was to determine which human tumors should be studied in phase II clinical trials with this agent. Eighty-eight out of 282 tumors plated in culture were evaluable for drug-sensitivity assays. The overall
in vitro response rate (defined as a ⩽50% survival of tumor colony-forming units compared to control) was 28% at 0.4
μg/ml (
1
10
of peak plasma level).
In vitro activity was noted for elliptinium against breast cancer, renal cell carcinoma, small-cell lung cancer and non small-cell lung cancer. Elliptinium had a higher
in vitro activity than adriamycin against this same group of tumors. Six of 25 (24%) adriamycin-resistant tumors were sensitive to elliptimium. Our
in vitro response rate in breast cancer correlates with the response rate in phase II clinical trials with this drug. Further phase II clinical trials with elliptinium in patients with renal cell carcinoma, non small-cell lung cancer and small-cell lung cancer are indicated. |
| doi_str_mv | 10.1016/0277-5379(87)90440-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77907751</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0277537987904408</els_id><sourcerecordid>77907751</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-c33073a75e83ba4cc1896330652b95f135f3b5deb9531ff4b909b374236ff0023</originalsourceid><addsrcrecordid>eNp9kE1PwyAYxzlodE6_gSYcjNHEKS200IvJMudLsuhFz4RS2DAtnUBn9u1lttnRC4T_y5OHHwDnCbpLUJLfo5TSSYZpcc3oTYEIQRN2AEZ7-RiceP-FUMpIho_AESYpwzgdgWpe12YdjDVdcwsFfHybQmODclLUIspLKJbKBvhjwgqWrhUVFDaY0DWtg0IGszFhGxuxuuoaYWHvyLq1u7Lf-qCaU3CoRe3V2XCPwefT_GP2Mlm8P7_OpouJxCwP8cSIYkEzxXApiJQJK_Ko5VlaFplOcKZxmVUqPnCiNSkLVJSYkhTnWse_4TG46ueuXfvdKR94Y7xUdS2sajvPKS0QpVkSg6QPStd675Tma2ca4bY8QXwHlO_I8R05zij_A8pZrF0M87uyUdW-NNCM_uXgCx_5aSesNH4fowSlRZrH2EMfU5HFxijHvTTKSlUZp2TgVWv-3-MXJy6TmA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77907751</pqid></control><display><type>article</type><title>Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Arteaga, Carlos L. ; Kisner, Daniel L. ; Goodman, Anita ; Von Hoff, Daniel D.</creator><creatorcontrib>Arteaga, Carlos L. ; Kisner, Daniel L. ; Goodman, Anita ; Von Hoff, Daniel D.</creatorcontrib><description>We have utilized a human tumor cloning system to determine the
in vitro antitumor effects of elliptinium, a new DNA intercalating agent. The purpose was to determine which human tumors should be studied in phase II clinical trials with this agent. Eighty-eight out of 282 tumors plated in culture were evaluable for drug-sensitivity assays. The overall
in vitro response rate (defined as a ⩽50% survival of tumor colony-forming units compared to control) was 28% at 0.4
μg/ml (
1
10
of peak plasma level).
In vitro activity was noted for elliptinium against breast cancer, renal cell carcinoma, small-cell lung cancer and non small-cell lung cancer. Elliptinium had a higher
in vitro activity than adriamycin against this same group of tumors. Six of 25 (24%) adriamycin-resistant tumors were sensitive to elliptimium. Our
in vitro response rate in breast cancer correlates with the response rate in phase II clinical trials with this drug. Further phase II clinical trials with elliptinium in patients with renal cell carcinoma, non small-cell lung cancer and small-cell lung cancer are indicated.</description><identifier>ISSN: 0277-5379</identifier><identifier>DOI: 10.1016/0277-5379(87)90440-8</identifier><identifier>PMID: 3428332</identifier><identifier>CODEN: EJCODS</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Alkaloids - therapeutic use ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Colony-Forming Units Assay ; Dose-Response Relationship, Drug ; Doxorubicin - pharmacology ; Drug Evaluation ; Ellipticines - therapeutic use ; Female ; General aspects ; Humans ; Intercalating Agents - therapeutic use ; Medical sciences ; Pharmacology. Drug treatments ; Tumor Stem Cell Assay</subject><ispartof>European journal of cancer & clinical oncology, 1987-11, Vol.23 (11), p.1621-1626</ispartof><rights>1987</rights><rights>1988 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-c33073a75e83ba4cc1896330652b95f135f3b5deb9531ff4b909b374236ff0023</citedby><cites>FETCH-LOGICAL-c386t-c33073a75e83ba4cc1896330652b95f135f3b5deb9531ff4b909b374236ff0023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7402926$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3428332$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arteaga, Carlos L.</creatorcontrib><creatorcontrib>Kisner, Daniel L.</creatorcontrib><creatorcontrib>Goodman, Anita</creatorcontrib><creatorcontrib>Von Hoff, Daniel D.</creatorcontrib><title>Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system</title><title>European journal of cancer & clinical oncology</title><addtitle>Eur J Cancer Clin Oncol</addtitle><description>We have utilized a human tumor cloning system to determine the
in vitro antitumor effects of elliptinium, a new DNA intercalating agent. The purpose was to determine which human tumors should be studied in phase II clinical trials with this agent. Eighty-eight out of 282 tumors plated in culture were evaluable for drug-sensitivity assays. The overall
in vitro response rate (defined as a ⩽50% survival of tumor colony-forming units compared to control) was 28% at 0.4
μg/ml (
1
10
of peak plasma level).
In vitro activity was noted for elliptinium against breast cancer, renal cell carcinoma, small-cell lung cancer and non small-cell lung cancer. Elliptinium had a higher
in vitro activity than adriamycin against this same group of tumors. Six of 25 (24%) adriamycin-resistant tumors were sensitive to elliptimium. Our
in vitro response rate in breast cancer correlates with the response rate in phase II clinical trials with this drug. Further phase II clinical trials with elliptinium in patients with renal cell carcinoma, non small-cell lung cancer and small-cell lung cancer are indicated.</description><subject>Alkaloids - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Colony-Forming Units Assay</subject><subject>Dose-Response Relationship, Drug</subject><subject>Doxorubicin - pharmacology</subject><subject>Drug Evaluation</subject><subject>Ellipticines - therapeutic use</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Intercalating Agents - therapeutic use</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumor Stem Cell Assay</subject><issn>0277-5379</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1PwyAYxzlodE6_gSYcjNHEKS200IvJMudLsuhFz4RS2DAtnUBn9u1lttnRC4T_y5OHHwDnCbpLUJLfo5TSSYZpcc3oTYEIQRN2AEZ7-RiceP-FUMpIho_AESYpwzgdgWpe12YdjDVdcwsFfHybQmODclLUIspLKJbKBvhjwgqWrhUVFDaY0DWtg0IGszFhGxuxuuoaYWHvyLq1u7Lf-qCaU3CoRe3V2XCPwefT_GP2Mlm8P7_OpouJxCwP8cSIYkEzxXApiJQJK_Ko5VlaFplOcKZxmVUqPnCiNSkLVJSYkhTnWse_4TG46ueuXfvdKR94Y7xUdS2sajvPKS0QpVkSg6QPStd675Tma2ca4bY8QXwHlO_I8R05zij_A8pZrF0M87uyUdW-NNCM_uXgCx_5aSesNH4fowSlRZrH2EMfU5HFxijHvTTKSlUZp2TgVWv-3-MXJy6TmA</recordid><startdate>19871101</startdate><enddate>19871101</enddate><creator>Arteaga, Carlos L.</creator><creator>Kisner, Daniel L.</creator><creator>Goodman, Anita</creator><creator>Von Hoff, Daniel D.</creator><general>Elsevier Ltd</general><general>Pergamon Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19871101</creationdate><title>Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system</title><author>Arteaga, Carlos L. ; Kisner, Daniel L. ; Goodman, Anita ; Von Hoff, Daniel D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-c33073a75e83ba4cc1896330652b95f135f3b5deb9531ff4b909b374236ff0023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Alkaloids - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Colony-Forming Units Assay</topic><topic>Dose-Response Relationship, Drug</topic><topic>Doxorubicin - pharmacology</topic><topic>Drug Evaluation</topic><topic>Ellipticines - therapeutic use</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Intercalating Agents - therapeutic use</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumor Stem Cell Assay</topic><toplevel>online_resources</toplevel><creatorcontrib>Arteaga, Carlos L.</creatorcontrib><creatorcontrib>Kisner, Daniel L.</creatorcontrib><creatorcontrib>Goodman, Anita</creatorcontrib><creatorcontrib>Von Hoff, Daniel D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer & clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arteaga, Carlos L.</au><au>Kisner, Daniel L.</au><au>Goodman, Anita</au><au>Von Hoff, Daniel D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system</atitle><jtitle>European journal of cancer & clinical oncology</jtitle><addtitle>Eur J Cancer Clin Oncol</addtitle><date>1987-11-01</date><risdate>1987</risdate><volume>23</volume><issue>11</issue><spage>1621</spage><epage>1626</epage><pages>1621-1626</pages><issn>0277-5379</issn><coden>EJCODS</coden><abstract>We have utilized a human tumor cloning system to determine the
in vitro antitumor effects of elliptinium, a new DNA intercalating agent. The purpose was to determine which human tumors should be studied in phase II clinical trials with this agent. Eighty-eight out of 282 tumors plated in culture were evaluable for drug-sensitivity assays. The overall
in vitro response rate (defined as a ⩽50% survival of tumor colony-forming units compared to control) was 28% at 0.4
μg/ml (
1
10
of peak plasma level).
In vitro activity was noted for elliptinium against breast cancer, renal cell carcinoma, small-cell lung cancer and non small-cell lung cancer. Elliptinium had a higher
in vitro activity than adriamycin against this same group of tumors. Six of 25 (24%) adriamycin-resistant tumors were sensitive to elliptimium. Our
in vitro response rate in breast cancer correlates with the response rate in phase II clinical trials with this drug. Further phase II clinical trials with elliptinium in patients with renal cell carcinoma, non small-cell lung cancer and small-cell lung cancer are indicated.</abstract><cop>Oxford</cop><cop>New York, NY</cop><pub>Elsevier Ltd</pub><pmid>3428332</pmid><doi>10.1016/0277-5379(87)90440-8</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-5379 |
| ispartof | European journal of cancer & clinical oncology, 1987-11, Vol.23 (11), p.1621-1626 |
| issn | 0277-5379 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77907751 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Alkaloids - therapeutic use Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Colony-Forming Units Assay Dose-Response Relationship, Drug Doxorubicin - pharmacology Drug Evaluation Ellipticines - therapeutic use Female General aspects Humans Intercalating Agents - therapeutic use Medical sciences Pharmacology. Drug treatments Tumor Stem Cell Assay |
| title | Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T14%3A15%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elliptinium,%20a%20DNA%20intercalating%20agent%20with%20broad%20antitumor%20activity%20in%20a%20human%20tumor%20cloning%20system&rft.jtitle=European%20journal%20of%20cancer%20&%20clinical%20oncology&rft.au=Arteaga,%20Carlos%20L.&rft.date=1987-11-01&rft.volume=23&rft.issue=11&rft.spage=1621&rft.epage=1626&rft.pages=1621-1626&rft.issn=0277-5379&rft.coden=EJCODS&rft_id=info:doi/10.1016/0277-5379(87)90440-8&rft_dat=%3Cproquest_cross%3E77907751%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77907751&rft_id=info:pmid/3428332&rft_els_id=0277537987904408&rfr_iscdi=true |